0000000000067944

AUTHOR

Stefanie Wagner

showing 25 related works from this author

Early improvement as a resilience signal predicting later remission to antidepressant treatment in patients with Major Depressive Disorder: Systemati…

2017

Early improvement of depressive symptoms during the first two weeks of antidepressant treatment has been discussed to be a resilience signal predicting a later positive treatment outcome in patients with Major Depressive Disorder (MDD). However, the predictive value of early improvement varies between studies, and the use of different antidepressants may explain heterogeneous results. The objective of this review was to assess the predictive value of early improvement on later response and remission and to identify antidepressants with the highest chance of early improvement. We included 17 randomized controlled trials investigating early improvement in 14,779 adult patients with MDD compar…

medicine.medical_specialtymedicine.drug_classmedia_common.quotation_subjectMirtazapineTricyclic antidepressantPlacebolaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineOutcome Assessment Health CaremedicineHumansPsychiatryBiological Psychiatrymedia_commonDepressive Disorder MajorResilience Psychologicalmedicine.diseaseAntidepressive Agents030227 psychiatryPsychiatry and Mental healthMeta-analysisAntidepressantMajor depressive disorderPsychological resiliencePsychology030217 neurology & neurosurgerymedicine.drugJournal of psychiatric research
researchProduct

Early onset of depression and treatment outcome in patients with major depressive disorder

2021

Major depressive disorder (MDD) is a highly heterogeneous disorder, which may partly explain why treatment outcome using antidepressants is unsatisfactory. We investigated the onset of depression as a possible clinical marker for therapy response prediction in the context of somatic biomarkers blood pressure and plasma electrolyte concentration. 889 MDD patients were divided into early (EO, n = 226), intermediate (IO, n = 493), and late onset (LO, n = 169) patients and were analyzed for differences in socio-demographic and clinical parameters, comorbidities and treatment outcome as well as systolic blood pressure and electrolytes. EO patients more often suffered from a recurrent depression,…

medicine.medical_specialtyTreatment outcomeLate onsetContext (language use)03 medical and health sciences0302 clinical medicineInternal medicineHumansMedicineIn patientAge of OnsetBiological PsychiatryDepression (differential diagnoses)Early onsetDepressive Disorder MajorDepressionbusiness.industrymedicine.diseaseAntidepressive Agents030227 psychiatryPsychiatry and Mental healthTreatment OutcomeBlood pressureMajor depressive disorderbusiness030217 neurology & neurosurgeryJournal of Psychiatric Research
researchProduct

Effects of age on depressive symptomatology and response to antidepressant treatment in patients with major depressive disorder aged 18 to 65 years

2020

Background: There is evidence that symptomatology in patients with major depressive disorder (MDD) changes with age. However, studies comparing depressive symptomatology between different age groups during antidepressant therapy are rare. We compared demographic and clinical characteristics in depressed patients of different age groups at baseline and during treatment. Methods: 889 MDD inpatients were divided into four age groups (18–29, 30–39, 40–49, 50–65 yrs.). Demographic and clinical characteristics including depressive symptomatology (assessed by the Inventory of Depressive Symptoms) were assessed at baseline and weekly during treatment. Results: At baseline, young patients (18–29 yea…

AdultMalePediatricsmedicine.medical_specialtyAdolescentlcsh:RC435-571IrritabilityDepressive symptomatology03 medical and health sciencesYoung Adult0302 clinical medicinelcsh:PsychiatrymedicineHumansIn patientDepression (differential diagnoses)AgedDepressive Disorder Majorbusiness.industryDepressionAge FactorsMiddle Agedmedicine.diseasePersonality disordersAntidepressive AgentsIrritable MoodSelf Concept030227 psychiatrySubstance abusePsychiatry and Mental healthClinical PsychologyTreatment OutcomeAntidepressantMajor depressive disorderFemalemedicine.symptombusiness030217 neurology & neurosurgeryComprehensive Psychiatry
researchProduct

WITHDRAWN: Association analysis between the early change of serum brain-derived neurotrophic factor (sBDNF) and final change of depression severity d…

2010

This article has been withdrawn at the request of the Editor-in-Chief. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.

PharmacologyBrain-derived neurotrophic factormedicine.medical_specialtyPsychiatry and Mental healthNeurologymedicineAntidepressantPharmacology (medical)Neurology (clinical)PsychiatryPsychologyBiological PsychiatryDepression (differential diagnoses)Clinical psychologyGenetic associationEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression – The EMC trial

2015

Patients with Major Depressive Disorder (MDD) and no improvement after two weeks of antidepressant pharmacotherapy have a high risk of treatment failure. The aim of the study was to determine whether an early medication change (EMC) strategy is superior to a guideline-based treatment in MDD patients without improvement after two weeks of antidepressant pharmacotherapy. Eight-hundred-and-eighty-nine patients with MDD were enrolled, 879 patients received the SSRI escitalopram. Of those, 192 patients had no improvement, defined as a reduction of < 20% on the Hamilton Depression Rating Scale (HAMD-17) after 14 days of treatment, and were randomly assigned to open treatment with the EMC strategy…

AdultMalemedicine.medical_specialtyAdolescentCitalopramLithiumCitalopramlaw.inventionDepressive Disorder Treatment-ResistantYoung Adult03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled triallawEarly Medical InterventionInternal medicinemedicineHumansEscitalopramPharmacology (medical)PsychiatryBiological PsychiatryAgedPharmacologyVenlafaxine HydrochlorideGuidelineMiddle Agedmedicine.diseaseAntidepressive Agents030227 psychiatryClinical trialPsychiatry and Mental healthTreatment OutcomeNeurologyDelayed-Action PreparationsAntidepressive Agents Second-GenerationAntidepressantMajor depressive disorderDrug Therapy CombinationFemaleNeurology (clinical)Psychology030217 neurology & neurosurgerymedicine.drugEuropean Neuropsychopharmacology
researchProduct

Modulatory role of the brain-derived neurotrophic factor Val66Met polymorphism on the effects of serious life events on impulsive aggression in borde…

2009

Impulsive aggression belongs to the key features of borderline personality disorder (BPD). In the development of BPD, serious life events are known to play a major role. Acute and chronic stress has been suggested to inhibit hippocampal brain-derived neurotrophic factor (BDNF) synthesis and to mediate neural plasticity in response to adverse social experiences. Recently it has been reported that the frequency of violent suicide attempts is higher in adult suicide attempters reporting severe childhood sexual abuse and carrying the Val(66)Val genotype of the BDNF Val(66)Met polymorphism. In this study we analysed modulating effects of BDNF Val(66)Met polymorphism on the effects of physical ma…

AdultMalemedicine.medical_specialtyHeterozygoteGenotypePoison controlSuicide preventionBehavioral NeuroscienceMethionineBorderline Personality Disordermental disordersInjury preventionNeuroplasticityGeneticsmedicineHumansChronic stressPsychiatryChildBorderline personality disorderBrain-derived neurotrophic factorPolymorphism GeneticBrain-Derived Neurotrophic FactorValineChild Abuse Sexualmedicine.diseaseAggressionNeurologySexual abuseImpulsive BehaviorFemalePsychologyClinical psychologyGenes, brain, and behavior
researchProduct

P01-92 - Early Changes are Associated with late Changes of BDNF Serum Levels in Inpatients with Major Depression During Short-term Antidepressant Tre…

2010

ObjectivesMean BDNF serum concentration is lower in patients with major depression (MD) as compared to healthy controls. BDNF increases during the course of antidepressant treatment. This increase has been associated with symptom amelioration. The aim of this study was to analyse the relation between early and late BDNF changes during antidepressant treatment.MethodsForty-six patients with MD according to DSM-IV were included for this study. Patients were treated as clinically indicated. Depression severity was assessed by HAMD-17 by trained raters from baseline to week 6 in weekly intervals. Serum at each visit (baseline, V1-V6) was obtained from whole blood after centrifugation with 1.000…

medicine.medical_specialtySerum concentrationPsychiatry and Mental healthEndocrinologynervous systemInternal medicinemedicineAntidepressantIn patientsense organsskin and connective tissue diseasesPsychiatryPsychologyDepression (differential diagnoses)Whole bloodEuropean Psychiatry
researchProduct

EPA-0703 – Performance of the hamilton depression rating subscales to predict antidepressant treatment response in the early course of treatment

2014

Early improvement ( EI ), i.e. a symptom reduction from baseline of at least 20% after 2 weeks, has been proven to be a clinically useful predictor for later treatment outcome. In most studies EI is identified by using the sum score of the Hamilton Depression Rating Scale (HAMD). Several unidimensional subscales of the HAMD exist, which have proven to be an economic measure of treatment change. Their ability to detect onset of improvement in comparison to the full HAMD has not been researched yet. The present study investigated in patients with major depression (MD) (1) whether the HAMD subscales are a valid and economic option to predict antidepressant treatment response in the early cours…

Predictive validityPsychiatry and Mental healthReceiver operating characteristicRating scaleMirtazapineHamdmedicineAntidepressantPsychologyParoxetineDepression (differential diagnoses)medicine.drugClinical psychologyEuropean Psychiatry
researchProduct

Effects of magnetic seizure therapy on anterograde and retrograde amnesia in treatment‐resistant depression

2019

Background Electroconvulsive therapy (ECT) is the gold standard for treatment-resistant depression (TRD). However, cognitive side effects, mainly anterograde and retrograde amnesia, frequently occur. Magnetic seizure therapy (MST) is tested using more focal seizure induction. However, the suggestion MST may be more beneficial than ECT because it causes fewer amnesia have not yet been comprehensively investigated using common neuropsychological testing specifically for ECT. We aimed to examine whether MST causes anterograde and retrograde amnesia. Methods Ten patients with TRD were treated with MST (8.9 [2] treatments) at 100% machine output, a frequency of 100 Hz and 657.4 (62) pulses per t…

AdultMalemedicine.medical_specialtyAnterograde amnesiamedicine.medical_treatmentAmnesiaNeuropsychological TestsAudiologybehavioral disciplines and activitiesDepressive Disorder Treatment-ResistantExecutive Function03 medical and health sciences0302 clinical medicineElectroconvulsive therapySeizuresmental disordersmedicineHumansElectroconvulsive Therapymedicine.diagnostic_testbusiness.industryRetrograde amnesiaNeuropsychological testMiddle AgedAmnesia Anterogrademedicine.disease030227 psychiatryPsychiatry and Mental healthClinical PsychologyMagnetic FieldsMagnetic seizure therapyBrain stimulationMental RecallAmnesia RetrogradeFemalemedicine.symptombusinesshuman activitiesTreatment-resistant depression030217 neurology & neurosurgeryDepression and Anxiety
researchProduct

Association between cingulum bundle structure and cognitive performance: an observational study in major depression.

2009

AbstractBackgroundMajor depression can be regarded as a systemic neurobehavioral disorder resulting from dysfunction of the limbic-cortical networks. The cingulum bundle represents a major association fiber tract of those networks. The aim of our study was to determine the association of brain structural tissue markers of the cingulum bundle and cognitive function in patients with major depression.MethodsRegion-of-interest-based analyses of the middle-anterior and middle-posterior cingulum bundle fractional anisotropy (FA) and mean diffusivity (MD) using color-coded diffusion-tensor imaging and neuropsychological assessment in 14 patients with major depression.ResultsFA of the middle-anteri…

Cingulate cortexMalemedicine.medical_specialtyObservationNeuropsychological Testsbehavioral disciplines and activitiesGyrus CinguliFunctional Laterality03 medical and health sciencesAssociation fiber0302 clinical medicinePhysical medicine and rehabilitationMemoryFractional anisotropymedicineHumansAttention030212 general & internal medicineEffects of sleep deprivation on cognitive performanceNeuropsychological assessmentDepression (differential diagnoses)Depressive Disorder Majormedicine.diagnostic_testCognitionMiddle Aged030227 psychiatryPsychiatry and Mental healthDiffusion Tensor ImagingAnisotropyFemalePsychologyNeuroscienceDiffusion MRIEuropean psychiatry : the journal of the Association of European Psychiatrists
researchProduct

Lack of modulating effects of the COMT Val158Met polymorphism on the association of serious life events (SLE) and impulsivity in patients with Border…

2009

Adultmedicine.medical_specialtyPolymorphism GeneticLife eventsValineCatechol O-MethyltransferaseImpulsivitymedicine.diseaseLife Change EventsPsychiatry and Mental healthMethionineBorderline Personality DisorderPolymorphism (computer science)Impulsive BehaviormedicineHumansIn patientmedicine.symptomPsychiatryPsychologyAssociation (psychology)Borderline personality disorderGenetic Association StudiesBiological PsychiatryJournal of Psychiatric Research
researchProduct

Depression and cognitive deficits as long-term consequences of thrombotic thrombocytopenic purpura

2017

BACKGROUND Thrombotic thrombocytopenic purpura (TTP) is an acute life-threatening microangiopathy with a tendency of relapse characterized by consumptive thrombocytopenia, microangiopathic hemolytic anemia, and spontaneous von Willebrand factor–induced platelet clumping leading to microthrombi. The brain is frequently affected by microthrombi leading to neurologic abnormalities of varying severity. STUDY DESIGN AND METHODS The aim of this observational cohort study was to investigate the prevalence of depression and cognitive deficits in 104 patients having survived acute TTP. TTP survivors were repeatedly assessed by means of different standardized questionnaires to evaluate depression (ID…

Pediatricsmedicine.medical_specialtybusiness.industryImmunologyMicroangiopathyThrombotic thrombocytopenic purpuraCognitionHematologyMicroangiopathic hemolytic anemia030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesImmunology and AllergyMedicineEffects of sleep deprivation on cognitive performanceYoung adultbusinessDepression (differential diagnoses)030215 immunologyCohort studyTransfusion
researchProduct

A combined marker of early non-improvement and the occurrence of melancholic features improve the treatment prediction in patients with Major Depress…

2017

Abstract Background Early Improvement of depressive symptoms within two weeks of antidepressant treatment is a highly sensitive but less specific predictor of later treatment outcome. The aim of this study was to identify clinical features at treatment initiation which are associated with early improvement and non-improvement as well as to identify variables predicting non-remission in patients showing an early improvement. Methods 889 patients with a major depressive episode according to DSM-IV who had participated in an antidepressant treatment trial served as study sample. Clinical predictors (demographic variables, psychopathology, comorbid disorders) were analysed in 698 (79%) early im…

AdultMalemedicine.medical_specialtyComorbidityAvoidant personality disorderPatient ReadmissionSeverity of Illness IndexSuicidal Ideation03 medical and health sciences0302 clinical medicineRisk FactorsRating scaleInternal medicinemedicineHumansMajor depressive episodePsychiatryAtypical depressionDepression (differential diagnoses)Depressive Disorder Majorbusiness.industryMiddle Agedmedicine.diseaseAntidepressive Agents030227 psychiatryPsychiatry and Mental healthClinical PsychologyTreatment OutcomeMajor depressive disorderAntidepressantFemalemedicine.symptombusiness030217 neurology & neurosurgeryPsychopathologyJournal of Affective Disorders
researchProduct

Association Between Citalopram Serum Levels and Clinical Improvement of Patients With Major Depression

2011

Imaging studies have shown that serum concentrations of the selective serotonin reuptake inhibitor citalopram correlate with serotonin transporter (5-HTT) occupancy in vivo. In patients with major depressive disorders treated with citalopram, 80% 5-HTT occupancy was considered to be necessary for maximal therapeutic effects, which requires citalopram serum concentrations of at least 50 ng/mL. The aim of this study was to compare treatment outcome in patients with citalopram serum concentrations greater than and less than 50 ng/mL after 7 days of treatment. This study included inpatients with acute major depressive disorder according to International Classification of Disease, 10th Revision …

Malemedicine.medical_specialtySerotonin reuptake inhibitorCitalopramCitalopramSeverity of Illness Indexbehavioral disciplines and activitiesGastroenterologyInternal medicinemental disordersSeverity of illnessmedicineHumansPharmacology (medical)Adverse effectDepressive Disorder Majormedicine.diagnostic_testTherapeutic effectLength of StayMiddle Agedmedicine.diseasePsychiatry and Mental healthTherapeutic drug monitoringAnesthesiaMajor depressive disorderFemaleDrug MonitoringReuptake inhibitorPsychologySelective Serotonin Reuptake Inhibitorsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

Association analysis between gene variants of the tyrosine hydroxylase and the serotonin transporter in borderline personality disorder.

2010

For patients with borderline personality disorder (BPD), we previously reported an independent effect of the catechol-o-methyl-transferase (COMT) low-activity (Met(158)) allele and an interaction with the low-expression allele of the deletion/insertion (short/long or S/L, resp.) polymorphism in the serotonin transporter-linked promoter region (5-HTTLPR). The purpose of the present study was to extend these findings to the tyrosine hydroxylase (TH) Val(81)Met single nucleotide polymorphism (SNP), the 5-HTTLPR S/L polymorphism incorporating the recently described functional A/G SNP within the long allele of the 5-HTTLPR (rs25531) as well as the variable number of tandem repeat (VNTR) polymorp…

medicine.medical_specialtyGenotypeTyrosine 3-MonooxygenaseGenome-wide association studySingle-nucleotide polymorphismCatechol O-MethyltransferasePolymorphism Single NucleotidePolymorphism (computer science)Borderline Personality DisorderInternal medicinemental disordersGenotypemedicineSNPHumansAlleleBiological PsychiatrySerotonin transporterAllelesGenetic associationGeneticsSerotonin Plasma Membrane Transport ProteinsbiologyGenetic VariationDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthEndocrinologyCase-Control Studiesbiology.proteinPsychologyGenome-Wide Association StudyThe world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
researchProduct

Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depressio…

2011

Abstract In Major Depressive Disorder, a growing data base suggests that the onset of antidepressants’ action can be detected by improvement of depressive symptoms in the first 10–14 days of treatment. Previous studies showed that the mean concentration of the brain-derived neurotrophic factor (BDNF) in blood increases during antidepressant treatment and positively correlates with amelioration of MDD symptoms. We previously showed an association between very early changes of the serum BDNF concentration and treatment outcome ( Tadic et al., 2011 . Prog Neuropsychopharmacol Biol Psychiatry 35, 415–420). However, no study has yet investigated whether BDNF concentration in plasma increases in …

OncologyAdultMalemedicine.medical_specialtyTime FactorsEnzyme-Linked Immunosorbent AssayCellular and Molecular NeuroscienceYoung AdultNeurotrophic factorsInternal medicineHamdmedicineHumansPsychiatryDepression (differential diagnoses)PharmacologyBrain-derived neurotrophic factorPsychiatric Status Rating ScalesDepressive Disorder MajorInpatientsBrain-Derived Neurotrophic FactorMiddle Agedmedicine.diseaseAntidepressive AgentsROC CurveLinear ModelsAntidepressantBiomarker (medicine)Major depressive disorderAnxietyFemalemedicine.symptomPsychologyNeuropharmacology
researchProduct

Early improvement of executive test performance during antidepressant treatment predicts treatment outcome in patients with Major Depressive Disorder

2017

Executive dysfunctions frequently occur in patients with Major Depressive Disorder and have been shown to improve during effective antidepressant treatment. However, the time course of improvement and its relationship to treatment outcome is unknown. The aim of the study was to assess the test performance and clinical outcome by repetitive assessments of executive test procedures during antidepressant treatment. Executive test performance was assessed in 209 –patients with Major Depressive Disorder (mean age 39.3 ± 11.4 years) and 84 healthy controls five times in biweekly intervals from baseline to week 8. Patients were treated by a defined treatment algorithm within the early medication c…

Malelcsh:MedicineSocial SciencesNeuropsychological TestsSeverity of Illness IndexExecutive FunctionCognition0302 clinical medicineMedicine and Health SciencesPsychologyVerbal fluency testlcsh:ScienceProspective cohort studyDepression (differential diagnoses)Cognitive ImpairmentMultidisciplinaryDepressionCognitive NeurologyPharmaceuticsCognitive flexibilityDrugsCognitionAntidepressantsMiddle AgedAntidepressive AgentsCognitive LinguisticsChemistryTreatment OutcomeNeurologyPhysical SciencesMajor depressive disorderFemaleResearch ArticleChemical ElementsAdultmedicine.medical_specialtyCognitive NeuroscienceLithium03 medical and health sciencesDrug TherapyNeuropsychologyRating scaleMental Health and PsychiatrySeverity of illnessmedicineHumansNeuropsychological TestingPharmacologyDepressive Disorder MajorMood Disordersbusiness.industrylcsh:RBiology and Life SciencesLinguisticsmedicine.disease030227 psychiatryCase-Control StudiesPhysical therapyCognitive Sciencelcsh:QbusinessPsychomotor Performance030217 neurology & neurosurgeryNeurosciencePLOS ONE
researchProduct

Gender differences in axis I and axis II comorbidity in patients with borderline personality disorder.

2008

&lt;i&gt;Background/Aims:&lt;/i&gt; Differences in the clinical presentation of men and women with borderline personality disorder (BPD) are of potential interest for investigations into the neurobiology, genetics, natural history, and treatment response of BPD. The purpose of this study was to investigate gender differences in axis I and axis II comorbidity and in diagnostic criteria in BPD patients. &lt;i&gt;Methods:&lt;/i&gt; 110 women and 49 men with BPD were assessed with the computer-based version of the Munich-Composite International Diagnostic Interview and the Structured Clinical Interview for DSM-IV Personality Disorders. Gender differences were investigated for the following outc…

NosologyAdultMalemedicine.medical_specialtyAnorexia NervosaBipolar DisorderCross-sectional studySubstance-Related DisordersComorbidityPersonality Assessmentbehavioral disciplines and activitiesPersonality DisordersYoung AdultSex FactorsBorderline Personality DisorderGermanymental disordersmedicineHumansIn patientYoung adultPsychiatryBorderline personality disorderDepressive DisorderMental DisordersFollow up studiesMiddle Agedmedicine.diseaseComorbidityAnxiety DisordersDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthClinical PsychologyAlcoholismCross-Sectional StudiesFemalePersonality Assessment InventoryPsychologyPsychopathology
researchProduct

Early Improvement and Serum Concentrations of Citalopram to Predict Antidepressant Drug Response of Patients with Major Depression

2013

Post hoc analyses of clinical trials have shown that early improvement around day 14 is highly predictive for later response. More- over, evidence has been given that suffi ciently high concentrations of antidepressant drugs in blood are required to attain response. In this study, we determined cut-off levels for citalo- pram serum concentrations and clinical improve- ment during the early phase of treatment to predict later response and the predictive power of these measures either alone or in combination. Methods: Inpatients with depressive disorder according to ICD-10 who received citalopram were included. Psychopathology was assessed by the 17-item Hamilton Depression (HAMD-17) rating s…

Malemedicine.medical_specialtyCitalopramCitalopramSensitivity and SpecificityPredictive Value of TestsRating scaleInternal medicinemedicineHumansPharmacology (medical)Depression (differential diagnoses)Depressive Disorder MajorReceiver operating characteristicGeneral MedicineOdds ratioMiddle AgedAntidepressive AgentsClinical trialPsychiatry and Mental healthAnesthesiaAntidepressantFemalePsychologyPsychopathologymedicine.drugPharmacopsychiatry
researchProduct

Clinical Predictors of Response to Magnetic Seizure Therapy in Depression

2019

Objectives Magnetic seizure therapy (MST) is a novel convulsive brain stimulation method in clinical testing, which is used as an alternative for electroconvulsive therapy in patients with treatment-resistant depression (TRD). Preliminary studies have suggested that MST leads to fewer cognitive adverse effects than electroconvulsive therapy but has similar efficacy. However, the clinical predictors of response to MST have not been evaluated yet. This study aimed to investigate whether these predictors can be identified in patients with TRD. Methods Thirty-eight patients with TRD were included. As clinical predictors for treatment response, we used the diagnosis, sex, age, family history, an…

AdultMalemedicine.medical_specialtyAnhedoniaMagnetic Field Therapymedicine.medical_treatmentNeuroscience (miscellaneous)Depressive Disorder Treatment-Resistant03 medical and health sciences0302 clinical medicineElectroconvulsive therapyPredictive Value of TestsSeizuresInternal medicinemedicineHumansFamily historyAtypical depressionDepression (differential diagnoses)AgedPsychiatric Status Rating ScalesDepressionbusiness.industryHamilton Rating Scale for DepressionMiddle Agedmedicine.disease030227 psychiatryPsychiatry and Mental healthTreatment OutcomeMagnetic seizure therapyBrain stimulationAnxietyFemalemedicine.symptombusinesshuman activities030217 neurology & neurosurgeryThe Journal of ECT
researchProduct

The catechol o-methyltransferase (COMT) val158met polymorphism modulates the association of serious life events (SLE) and impulsive aggression in fem…

2009

Wagner S, Baskaya O, Anicker NJ, Dahmen N, Lieb K, Tadic A. The catechol o‐methyltransferase (COMT) val158met polymorphism modulates the association of serious life events (SLE) and impulsive aggression in female patients with borderline personality disorder (BPD). Objective: We analyzed i) the effects of serious life events (SLE) on impulsive aggression, and ii) modulating effects of the COMT Val158Met polymorphism on the association between SLEs and impulsive aggression in borderline personality disorder (BPD). Method: One hundred and twelve female BPD patients from Germany were included in this study. Impulsive aggression was assessed by the Buss‐Durkee‐Hostility Inventory (BDHI). Result…

Child abusemedicine.medical_specialtyCatechol-O-methyl transferaseAggressionPoison controlImpulsivitymedicine.diseasebehavioral disciplines and activitiesGenetic determinismPsychiatry and Mental healthSexual abusemental disordersmedicinemedicine.symptomPsychiatryPsychologyBorderline personality disorderActa Psychiatrica Scandinavica
researchProduct

Body mass index (BMI) in major depressive disorder and its effects on depressive symptomatology and antidepressant response

2019

Obesity is one of the most prevalent somatic comorbidities of Major Depressive Disorder (MDD). We aimed to investigate the relationship between body mass index (BMI) and MDD, the symptomatology of the disorder as well as the outcome of antidepressant treatment.Early medication change (EMC) trial participants with BMI measurement (n = 811) were categorized according to WHO-criteria in normal or low weight (BMI  25), overweight (25- 30), and obese (≥30). Depression severity and BMI was assessed in weekly intervals up to 8 weeks. BMI at baseline and course of BMI during the study were investigated in linear regression models as possible moderators of therapy response. Possible moderators such …

AdultMalemedicine.medical_specialtyComorbidityOverweightWeight GainBody Mass IndexDepressive symptomatology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansObesityDepression (differential diagnoses)Depressive Disorder Majorbusiness.industryMiddle Agedmedicine.diseaseObesityAntidepressive Agents030227 psychiatryPsychiatry and Mental healthClinical PsychologyAntidepressantMajor depressive disorderFemalemedicine.symptombusinessWeight gainBody mass index030217 neurology & neurosurgeryJournal of Affective Disorders
researchProduct

The Amount of Mitochondrial DNA in Blood Reflects the Course of a Depressive Episode

2016

AdultMalePsychiatric Status Rating ScalesGeneticsDepressive DisorderMitochondrial DNAbusiness.industryMiddle AgedBioinformaticsDNA Mitochondrial030227 psychiatryYoung Adult03 medical and health sciences0302 clinical medicineDisease ProgressionHumansMedicineFemaleLongitudinal Studiesbusiness030217 neurology & neurosurgeryBiological PsychiatryBiological Psychiatry
researchProduct

Does a cognitive-training programme improve the performance of middle-aged employees undergoing in-patient psychosomatic treatment?

2008

Purpose. With the ever-increasing average life expectancy and rising age of retirement, cognitive and work capacities in advanced age take on great importance. Cognitive impairments, however, increase with age. The effect of cognitive-training programmes on people with mild cognitive impairment has not been verified in any systematic investigations.Method. This study presents a cognitive-training programme designed for middle-aged employees that was implemented and evaluated at the Psychosomatic Clinic Bad Neustadt/Saale in an AB study design (A: no intervention; B: intervention).Results. Memory performance of the intervention group (n = 33) improved significantly between intake and dischar…

MaleMemory Disordersmedicine.medical_specialtyFuture studiesCognitive Behavioral TherapyRehabilitationCognitionIntervention groupMiddle AgedNeuropsychological TestsPsychophysiologic DisordersCognitive trainingSurveys and QuestionnairesIntervention (counseling)Employee Performance AppraisalPhysical therapymedicineLife expectancyHumansFemaleIn patientCognition DisordersCognitive impairmentPsychologyOccupational HealthDisability and Rehabilitation
researchProduct

P-491 - Sensitivity to changes during antidepressant treatment: a comparison of unidimensional depression rating scales in patients with minor depres…

2012

In the efficacy evaluation of antidepressant treatments the total score of the Hamilton Depression Rating Scale (HAMD) is still regarded as the’gold standard’. Studies suggest that unidimensional subscales of the HAMD, which capture the core depressive symptoms, outperform the full HAMD regarding the detection of antidepressant treatment effects. The present study compared several unidimensional subscales of the HAMD and the Inventory of Depressive Symptomatology (IDS) regarding their sensitivity to changes in depression symptoms in a sample of patients with minor depression (MIND). Biweekly IDS-C28 and HAMD17 data from 287 patients of a 10-week randomised, placebo-controlled trial comparin…

Sertralinemedicine.medical_specialtymedicine.medical_treatmentShort scaleGroup psychotherapyPsychiatry and Mental healthRating scaleHamdmedicineAntidepressantIn patientPsychologyPsychiatryDepression (differential diagnoses)Clinical psychologymedicine.drugEuropean Psychiatry
researchProduct